If medically feasible, patients taking regular medication, with the exception of potent inducers of CYPA, should be maintained on it throughout the study period; patients taking concomitant medications whose disposition is dependent upon breast cancer resistance protein (BCRP) and which have a narrow therapeutic index should be closely monitored for signs of changed tolerability as a result of increased exposure of the concomitant medication whilst receiving osimertinib\r\nNOTE: Use of St Johns wort is a contra-indication for osimertinib use
Patients must not be taking oral glucocorticoids at the time of registration
In case of use of oral contraception women should have been stable on the same pill for a minimum of  months before taking study treatment
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients must not be participating in any other clinical trial or taking any other experimental medications within  days prior to registration
Currently taking  or more anti-hypertensive medications
Currently taking disease modifying rheumatoid drugs (DMRDs)
Patients must not be taking medicines known to influence sirolimus metabolism
Patients taking a cholesterol lowering agent must be on a single medication and on a stable dose for at least  weeks
Agree to abstain from donating blood while taking IP and for at least  days following discontinuation of IP.
Patients taking nitrates
Patients taking PDE inhibitors more than /week during the previous  days
Women taking estrogen containing contraceptives or Hormone Replacement Therapy (HRT) must discontinue the treatment a minimum of  months prior to the screening mammogram. Progestin only contraceptives are permitted.
Patients can continue taking what they are taking at the time they start on the study, but agree not to start any new (over the counter) herbal supplement on regular basis during study duration
Participant is currently taking topiramate (Topamax) commonly used in epilepsy or to prevent migraines or other carbonic anhydrase inhibitors (e.g. zonisamide [Zonegran]; acetazolamide [Diamox Sequels]; or dichlorphenamide [Keveyis, Daranide])
Participant taking medications that might interact with cUAB
Taking cimetidine or allopurinol; if currently taking either of these medications, patient must discontinue for one week before receiving treatment with nab-paclitaxel
Subject is taking any oral anticoagulant
Patients who are taking immunosuppressive medication
Chronically taking an oral medication known to be a P-gp substrate within  days of starting treatment with Oratecan.
No history of bleeding problems; not taking aspirin or any medication that may affect erythrocyte biochemistry
Patients taking folic acid are eligible if the folic acid is discontinued prior to pyrimethamine administration and not taken for the duration of time enrolled on this study
Patients taking injections of long-acting SRLs not as indicated in the label
Subjects already taking drugs known to be -lipoxygenase inhibitors
Subjects taking anti-coagulants or platelet inhibitors
In case of use of oral contraception, women should have been stable on the same pill for a minimum of  months before taking study treatment
Currently taking immunosuppressive drugs within  days of study product injection (with exception of corticosteroids for tumor treatment)
Only for subjects enrolled in Arm  - Neratinib and everolimus: patients who are taking medications with moderate or potent inhibitors or inducers of CYP A should be off for  half-lives prior to starting everolimus.
Only for subjects enrolled in Arm  - Neratinib and palbociclib: patients who are taking medications with moderate or potent inhibitors or inducers of CYP A should be off for  half-lives prior to starting palbociclib.
Patients who are currently taking any medications for systemic anticoagulation other than aspirin will not be eligible
Patients currently taking anticoagulants
For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least  months prior to signing the ICF.
Currently taking a concomitant medication, other than a premedication, that is:
Treatment with the following medications are contraindicated with DSF when taken within  days prior to the first dose of DSF plus (+) Cu: metronidazole, isoniazid, dronabinol, carbocisteine, lopinavir, paraldehyde, ritonavir, sertraline, tindazole, tizanidine, atazanavir; (Note: the following medications are not contraindicated but should be cautioned if taking concurrently with DSF: warfarin, phenytoin, theophylline, chlorzoxazone, chlordiazepoxide, diazepam; if the patient is taking warfarin, international normalized ratio [INR] should be monitored closely; if the patient has to remain on phenytoin, its serum concentration and response should be monitored closely)
Taking warfarin sodium; patients on other blood thinners should be monitored for thrombocytopenia
Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than  days prior to starting mebendazole therapy
Patients must be capable of taking and absorbing oral medications
Patients taking sorivudine or brivudine must be off of these drugs for  weeks prior to starting capecitabine; patients taking cimetidine must have this drug discontinued; ranitidine or a drug from another anti-ulcer class can be substituted for cimetidine if necessary; if patient is currently receiving allopurinol, must discuss with principal investigator (PI) to see of another agent may substitute for it
Patients with diabetes on a different agent or patients with rheumatoid arthritis taking hydroxychloroquine (Plaquenil)
Taking psychotropic, anticonvulsive, or narcotic medication
Patients who are taking antiplatelet or anticoagulant agents - patients taking  mg of aspirin will be allowed with close observation
Patients who are currently taking or plan to take curcumin during the study
Currently taking phenytoin or phenobarbital
Currently taking cholestyramine or orlistat
Patients must not be participating in any other clinical trial or taking any other experimental medications within  days prior to registration
Patients who are currently taking omega- fatty acids
DONOR: Currently taking lithium therapy
If taking immunosuppressants, retinoids or anti-neutrophil therapy, participants must maintain stable doses of these medications during the  weeks prior to study initiation
Patients taking a potent CYPA inhibitor that cannot be changed to an alternate drug.
Patients taking immunosuppressants (corticosteroids to prevent/treat brain edema are permitted).
Patients who are taking immunosuppressive medication
Currently taking ibrutinib and first took ibrutinib >  months ago
Inability to continue taking ibrutinib for any reason
Currently taking lithium therapy
Part : not currently taking methylphenidate, or have taken it within the previous  days
Patients taking medications with known significant drug interactions
Currently taking systemic medications that would affect BCC tumors (oral retinoids) or metabolism of itraconazole (anti convulsants and corticosteroids); itraconazole should not be taken with cisapride (Propulsid), dofetilide (Tikosyn), oral midazolam (Versed), nisoldipine (Sular), pimozide (Orap), quinidine (Quinaglute), triazolam (Halcion), or levomethadyl (Orlaam), lovastatin (Mevacor), simvastatin (Zocor), or an ergot medication such as dihydroergotamine (Migranal), ergometrine or ergonovine (Ergotrate Maleate), ergotamine (Ergomar), or methylergometrine or methylergonovine (Methergine)
Immunosuppressed patients (cancer, autoimmune disease) or patients taking immunosuppressive drugs
Ability to swallow medication capsules by mouth (which may include taking nilotinib mixed in apple sauce)
Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria
Taking any substrate agents for CYP B (bupropion, cyclophosphamide, efavirenz, ifosfamide, methadone, paclitaxel, amodiaquine, repaglinide)
Taking any UGT A and UGT A substrates (e.g. irinotecan)
Taking P-Gp substrates (e.g. Digoxin)
Patients must not be currently taking or have ever taken vorinostat (Zolinza, Merck), panobinostat (Farydak, Novartis) or romidepsin (Istodax, Gloucester Pharmaceuticals)
Not currently taking steroids
Patients must not be participating in any other therapeutic clinical trial or taking any other experimental medications within  days prior to registration
Patients taking ruxolitinib at the time of enrollment must have been taking ruxolitinib for a minimum of  months, and must have been on a stable dose of ruxolitinib for a minimum of  weeks immediately prior to enrollment
Taking oral itraconazole
Taking any medication known to affect hedgehog (HH) signaling pathway
Patients taking aspirin for previously diagnosed cardiovascular disease
Patients taking immunosuppressive medications
Currently taking imatinib, dasatinib, nilotinib or bosutinib
Poor compliance with taking TKI
Women taking medications for which interaction with simvastatin may result in increased levels of simvastatin are not eligible
Patients taking medications that may have adverse interactions with enzalutamide
Currently taking bupropion (bupropion hydrochloride) for depression
Patient taking varenicline or bupropion within one month of study enrollment
Is taking or has taken any medications or therapies outside of protocol-defined parameters
Patients taking a cholesterol-lowering agent must be on a single medication and on a stable dose for at least  weeks
Currently taking hormone replacement therapy (local or systemic) (patients must discontinue for  weeks in order to be eligible prior to study enrollment)
Patients who are taking any anti-convulsant medication that interferes with the cytochrome P pathway (e.g. phenytoin, phenobarbital, carbamazepine, etc.)
Patients that are currently taking any prohibitive medication; patients on therapeutic dose of warfarin
Subjects taking nucleoside analog medications such as those used as antiretroviral agents
Are currently taking insulin
Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria
Males and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab and during five months for men, taking into account the characteristics of methotrexate
Males and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab and during five months for men, taking into account the characteristics of methotrexate.
Patients already taking HCQ or chloroquine for other diagnosis
FOR FIRST COHORT ONLY, NOT REQUIRED FOR BIOMARKER COHORT: Patients will be allowed to eat pomegranates and drink pomegranate juice provided that the patient has been taking these for  weeks or more with evidence of progressive disease as outlined above; these patients should be instructed to continue to take pomegranates and/or pomegranate juice as per the same schedule while on study; documentation of amount and duration will be captured for those patients taking pomegranates or pomegranate juice; those patients who have not been taking pomegranates or pomegranate juice prior to study entry will not be allowed to begin these while on study
Every effort should be made to switch patients taking drugs that are known to be sensitive substrates of these enzymes to other medications  week prior to starting therapy; if a patients medication cannot be switched, the patients eligibility will be determined following a review of their case by the principal investigator
Patients taking tolbutamide, warfarin, zidovudine, benzodiazepines, clonazepam, diazepam
Patients taking COX- inhibitors
Patients taking chronic erythropoietin are permitted provided no dose adjustment is made within  months prior to start of first dose.
Be currently taking or have previously taken testosterone, methyltestosterone, oxandrolone (Oxandrin), oxymetholone, danazol, fluoxymesterone (Halotestin), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), or anti-androgens
In case of use of oral contraception women should have been stabile on the same pill for a minimum of  months before taking study treatment.
Patients taking other commercially available medications which may theoretically either stimulate or inhibit autophagy, which are calcitriol and chloroquine
Patients taking medications which may lead to interactions with hydroxychloroquine, including penicillamine, telbivudine, botulinum toxin, digoxin, and propafenone
Must not be taking hydroxychloroquine for treatment or prophylaxis of malaria
The eligibility of patients taking medications that are potent inducers or inhibitors of that enzyme will be determined following a review of their case by the principal investigator; every effort should be made to switch patients taking such agents or substances to other medications before they begin treatment with one of the experimental drug included in this protocol, particularly patients with gliomas or brain metastases who are taking enzyme-inducing anticonvulsant agents
Agree to abstain from donating blood while taking IP and following discontinuation of IP.
Patients who were taking or have a history of taking letrozole or another aromatase inhibitor.
Subjects must not have been taking any lithium or lithium containing medications within  days prior to study enrollment
Patients currently taking medications with known rosuvastatin interactions including cyclosporine, gemfibrozil, lopinavir/ritonavir, atazanavir/ritonavir, coumarin anticoagulants, colchicine, fenofibrates, and niacin
Patients who are taking simvastatin or lovastatin. Patients should be switched to alternative therapies a minimum of  weeks before starting study drug
Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid
Taking other excluded medications
Subjects taking any other investigational drug used to research or treat PIV.
Currently taking systemic medications that would affect BCC tumors (oral retinoids) or metabolism of Itraconazole (anti-convulsants, corticosteroids)
Any patient taking hydroxychloroquine for treatment or prophylaxis of malaria
Patients who are currently taking immunosuppressive medications
Be taking benzodiazepines
Be taking anticholinergic medications
Be taking amifostine (Ethiofos)
Patients may not currently be taking quinidine, ceritinib, highest risk corrected QT interval (QTc)-prolonging agents, mifepristone, or succinylcholine
Patients must not be currently taking or planning to take during study treatment the following medications:\r\n* B agonists\r\n* Bosutinib\r\n* Ceritinib\r\n* Floctafenine\r\n* Methacholine\r\n* Pazopanib\r\n* Rivastigmine\r\n* Vincristine\r\n* Silodosin
Patients taking lithium
PHASE I: Currently taking AET
If taking anti-neuropathy medications, they are on a stable regimen (no change in  months)
If taking anti-neuropathy medications, they are on a stable regimen (no change in  months)
Physician determines implant volume appropriate for the patient taking into account the subject's BMI and chest width
Patients currently taking anabolic steroids will be excluded; patients taking corticosteroids are allowed on study
Patients taking nitrates (e.g., nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) and/or alpha blockers (e.g., tamsulosin, prazosin, afluzosin, silodosin) are not eligible.
Patients taking Viagra must have a  day washout period prior to treatment.\r\n* Note: patients must agree to discontinue Viagra while on study treatment.
Females who have been diagnosed with breast cancer and currently taking toremifene
Patients taking antibiotics or who plan to begin taking antibiotics
EXCLUSION - STUDY : Taking medications unrelated to cancer treatment that may affect balance and gait
If patient is taking systemic therapy for cGVHD at the time of enrollment, they must be on a stable or tapering doses in the preceding  weeks
Patients who are taking any antipsychotic medications
Patients who are currently taking melatonin must discontinue melatonin for  days before enrolling in the study
History of seizure or currently taking anti-epileptic medication
Subjects taking Digitalis are ineligible
Subjects taking selective serotonin reuptake inhibitors (SSRIs).
Patients who are taking any antipsychotic medications.
Patients taking immunosuppressive medications (other than dexamethasone) will be excluded
Patients who are receiving treatment with narcotics, tramadol, gabapentin, and/or pregabalin must have been taking a stable dose for at least  days prior to registration
SCREENING PHASE: Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine
INTERVENTION PHASE: Currently taking anti-neuropathy medication such as gabapentin, pregabalin, duloxetine, or glutamine
Patients taking any tetracycline within the last  days
Patients with medical restrictions that may interfere with or prevent them from taking part in the yoga interventions per their physicians decision
Patients taking any tetracycline in the last  days
Participant currently is taking melatonin
Currently taking MP or have taken it within the previous  days
Patients must currently be taking a third-generation aromatase inhibitor (AI)  anastrozole, letrozole, or exemestane for at least the previous  days prior to registration with plans to continue for at least an additional  year after registration; patients may have switched AIs provided that they have been on a stable dose for at least  days; concurrent trastuzumab (Herceptin) is allowed
Patients taking didanosine, azathioprine, or nucleoside reverse transcriptase inhibitors
Be currently taking MP or have taken it within the previous  days
Currently taking ginseng, methylphenidate or modafinil or have taken it within the previous  days
Patients taking concomitant alpha-adrenergic blocking agents
Patients taking other phosphodiesterase Type  (PDE) inhibitors
Currently taking anti-hypertensive medications
Be taking anticoagulant medication (does not include aspirin)
Participants taking illegal drugs
Currently taking ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil
Patient must not be taking chemoprevention for breast cancer
Currently taking psychotropic or cardiovascular medication
Currently taking psychotropic or cardiovascular medication
Is taking risk reduction therapy with tamoxifen
Patient unable to sit up or stay up for  minutes after taking oral dose
Women who are taking rapamycin for another diagnosis
Not currently taking aspirin (any dose) within the last  months
Interested in taking  months of varenicline
ELIGIBILITY FOR THE -YEAR EXTENSION: Patient is currently taking finasteride or dutasteride
A willingness to avoid taking NSAIDs outside of the trial (rare NSAID use for musculoskeletal symptoms excepted)
Not currently prescribed or taking nicotine replacement therapy or varenicline during this hospitalization
Currently taking spironolactone
Taking active cancer treatment
Participants cannot be taking -alpha-reductase inhibitors while on study or within  months of the baseline study visit
Participants may not be taking carbamazepine (tegretol)
Currently taking postmenopausal hormone replacement therapy
Males enrolled into treatment arms receiving CC- must: Agree to abstain from donating sperm while taking IP and for at least  months following discontinuation of IP
Currently taking fish oil supplements
Participants may not be taking medications that might interact with cUAB
Participants may not be taking lipid lowering agents
Taking prescribed medication to control their lipids
Taking Bean-O, other anti-flatulence medications or prolonged antibiotic use (one month)
Interested in taking  months of varenicline
If patients are routinely taking a multivitamin supplement, they will be asked to continue the supplement as long as the amount of vitamin D in the supplement is not in excess of the RDA (recommended daily allowance); if they are not taking a multivitamin supplement, they will be asked to not start supplementation while on study
Subjects taking thiazides (which can decrease urinary excretion of calcium)
Patients taking phenobarbital, digitalis, thiazides or ketoconazole
Patients taking digoxin or patients who are susceptible to calcium-related dysrhythmias
Patients taking danazol
Patients taking aluminum-based antacids
For patients highly suspected to have aGVHD and requiring systemic therapy only: Taking steroid treatment for suspected aGVHD for  days or less.
Patients taking retinoid medications by mouth (such as acitretin, isotretinoin), strontium ranelate may not take demeclocycline because of toxic interactions
Patients taking any tetracycline class of drug (i.e. minocycline, etc)
Participants who are taking a beta blocker at the time of the investigational exam are excluded
Currently taking imperative medications with significant drug-drug interaction with ciprofloxacin
Patients currently taking other sedative hypnotic medications
Taking active cancer treatment
Are currently taking a statin or have taken a statin in the past  months or have a history of an allergic reaction or intolerance at any time to a statin
Are taking a drug that may significantly interact or influence the metabolism of atorvastatin
Current usage of VPA or Dex, if patient has been on these medications in the past but is not currently taking them she is still a candidate for the study; prior use must be greater than one month for VPA; there is no wash out period required for DEX
Actively taking blood thinning agents (with the exception of low dose aspirin { m
Patients who are or will be taking other unapproved (i.e. not cleared/approved by the\n             FDA) anti-neoplastic therapies concurrently are not eligible (exception: ET with\n             everolimus is acceptable).
Currently taking anticoagulant medications or clopidogrel
Inability to abstain from taking anything by mouth for at least  hours
Currently taking a concomitant medication